IL179856A - Use of alemtuzumab monoclonal antibody in formulating an hiv medicament - Google Patents

Use of alemtuzumab monoclonal antibody in formulating an hiv medicament

Info

Publication number
IL179856A
IL179856A IL179856A IL17985606A IL179856A IL 179856 A IL179856 A IL 179856A IL 179856 A IL179856 A IL 179856A IL 17985606 A IL17985606 A IL 17985606A IL 179856 A IL179856 A IL 179856A
Authority
IL
Israel
Prior art keywords
alemtuzumab
formulating
monoclonal antibody
hiv medicament
hiv
Prior art date
Application number
IL179856A
Other languages
English (en)
Other versions
IL179856A0 (en
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of IL179856A0 publication Critical patent/IL179856A0/en
Publication of IL179856A publication Critical patent/IL179856A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL179856A 2004-08-30 2006-12-05 Use of alemtuzumab monoclonal antibody in formulating an hiv medicament IL179856A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60517304P 2004-08-30 2004-08-30
PCT/EP2005/008325 WO2006024354A1 (en) 2004-08-30 2005-07-28 Treatment of hiv infection by t-cell modulation

Publications (2)

Publication Number Publication Date
IL179856A0 IL179856A0 (en) 2007-05-15
IL179856A true IL179856A (en) 2010-11-30

Family

ID=35079284

Family Applications (1)

Application Number Title Priority Date Filing Date
IL179856A IL179856A (en) 2004-08-30 2006-12-05 Use of alemtuzumab monoclonal antibody in formulating an hiv medicament

Country Status (14)

Country Link
US (1) US20060057620A1 (https=)
EP (1) EP1784217A1 (https=)
JP (1) JP2008511559A (https=)
KR (1) KR20070050934A (https=)
AU (1) AU2005279460A1 (https=)
BR (1) BRPI0514729A (https=)
CA (1) CA2570735A1 (https=)
IL (1) IL179856A (https=)
MX (1) MX2007002188A (https=)
NO (1) NO20071700L (https=)
RU (1) RU2393872C2 (https=)
TW (1) TW200626172A (https=)
WO (1) WO2006024354A1 (https=)
ZA (1) ZA200702654B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008829A1 (en) * 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor

Also Published As

Publication number Publication date
KR20070050934A (ko) 2007-05-16
US20060057620A1 (en) 2006-03-16
WO2006024354A1 (en) 2006-03-09
ZA200702654B (en) 2008-08-27
CA2570735A1 (en) 2006-03-09
AU2005279460A1 (en) 2006-03-09
NO20071700L (no) 2007-05-29
IL179856A0 (en) 2007-05-15
EP1784217A1 (en) 2007-05-16
TW200626172A (en) 2006-08-01
JP2008511559A (ja) 2008-04-17
BRPI0514729A (pt) 2008-06-24
RU2393872C2 (ru) 2010-07-10
MX2007002188A (es) 2007-10-16
RU2007111566A (ru) 2008-10-10

Similar Documents

Publication Publication Date Title
IL193904A0 (en) Anti-igf-1r human monoclonal antibody formulation
IL190502A0 (en) Anti-addl monoclonal antibody and use thereof
EP1717250A4 (en) MONOCLONAL ANTIBODY AND ITS USE
IL179672A (en) Monoclonal antibodies against 3 cd human
IL179140A0 (en) Antibody drug conjuates and methods
IL186659A0 (en) Il-31 monoclonal antibodies and methods of use
IL181738A (en) Pharmaceutical compositions containing antibodies against her2
IL240179A0 (en) Use of a chimeric human monoclonal antibody that binds to il-5r in the production of a drug to reduce the number of basophils in a person's blood
IL185483A (en) Composition of anti-4-ctla antibody and their use in the preparation of anti-neoplastic drugs
PT1704166E (pt) Anticorpo monoclonal específico de m-csf e respetivos usos
IL231169A0 (en) Human monoclonal antibodies to fucosil - 1gm and methods of using antibodies against fucosil - 1gm
SI2594586T1 (sl) IL-31 monoklonska protitelesa in metode uporabe
EP1658095A4 (en) ANTI-CD3 ANTIBODY DESIMMUNISE
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
EP1633785A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST BACILLUS ANTHRACIS PROTECTIVE ANTIGEN
IL183251A0 (en) Antigenic epitopes of interleukin-21, related antibodies and heir use medical field
IL214779A (en) Isolated monoclonal antibody or epitope-binding antibody on cadm1, methods of preparation and use for drug preparation
IL180789A (en) Monoclonal human antibody against human 4 IL
HRP20140271T1 (hr) Humana antitijela protiv bjesnoä†e i njihova uporaba
PT2119452T (pt) Composição farmacêutica que compreende um anticorpo monoclonal anti-cd6 utilizado no diagnóstico e tratamento de artrite reumatoide
EP2077325A4 (en) MONOCLONAL ANTIBODY AND ITS USE
IL179856A (en) Use of alemtuzumab monoclonal antibody in formulating an hiv medicament
ZA200801874B (en) Antigenic peptides and their use
IL178311A0 (en) Stabilised tat antigen and the use thereof for anti-hiv vaccination
EP1753400A4 (en) PHARMACEUTICAL FOR ZIPRASIDONE

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees